Contineum Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
CTNM$10.30+8.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Years Ended | ||
|---|---|---|
| December 31, | ||
| 2024 | 2023 | |
| Operating activities | ||
| Net income (loss) | $(42,258) | $22,720 |
| Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities: | ||
| Depreciation and amortization | 258 | 195 |
| Non-cash operating lease expense | 872 | 965 |
| Stock-based compensation | 6,804 | 2,219 |
| Accretion of debt discount and debt issuance costs | — | (198) |
| Accretion of premiums/discounts on marketable securities, net | (3,940) | (2,675) |
| Change in fair value of warrant liability | 106 | (5) |
| Gain on sale of equipment | (16) | — |
| Change in fair value of investor rights and obligations liability | — | (2,867) |
| (Gain) loss on marketable securities | (5) | 19 |
| Changes in operating assets and liabilities | ||
| Prepaid expenses and other current assets | 887 | (1,277) |
| Other long-term assets | 937 | 7 |
| Accounts payable | 1,141 | — |
| Accrued expenses | 2,303 | 1,594 |
| Other long-term liabilities | — | (20) |
| Operating lease liabilities | 66 | (1,328) |
| Net cash provided by (used in) operating activities | (32,845) | 19,349 |
| Investing activities | ||
| Purchase of property and equipment | (514) | (414) |
| Proceeds from sale of equipment | 20 | — |
| Purchases of marketable securities | (226,407) | (141,866) |
| Sales and maturities of marketable securities | 157,162 | 76,712 |
| Net cash used in investing activities | (69,739) | (65,568) |
| Financing activities | ||
| Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs | 108,211 | — |
| Proceeds from issuance of Series C convertible preferred stock, net of offering costs | — | 60,138 |
| Payments of deferred offering costs | — | (343) |
| Principal payments on debt | — | (3,750) |
| Proceeds from exercise of stock options | 405 | 159 |
| Proceeds from employee stock purchase plan | 385 | — |
| Repurchase of restricted stock | — | (28) |
| Net cash provided by financing activities | 109,001 | 56,176 |
| Net increase in cash and cash equivalents | 6,417 | 9,957 |
| Cash and cash equivalents at beginning of year | 15,526 | 5,569 |
| Cash and cash equivalents at end of year | $21,943 | $15,526 |
| Supplemental disclosure of cash flow information | ||
| Income taxes paid | $— | $450 |
| Interest paid | $— | $150 |
| Supplemental disclosure of non-cash investing and financing activities | ||
| Deferred offering costs included in accounts payable and accrued liabilities | $— | $905 |
| Property and equipment purchases included in accounts payable | $58 | $30 |
| Conversion of convertible preferred stock to common stock upon initial public offering | $192,620 | $— |
| Reclassification of warrants from liability to equity | $216 | $— |
| Reclassification of deferred offering costs paid in prior year to equity | $343 | $— |
| Right-of-use assets obtained in exchange for lease liabilities | $5,620 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.